Table 1 The characteristics of the study groups
From: The effects of the covid-19 pandemic on puberty: a cross-sectional, multicenter study from Turkey
Pre-pandemic | Pandemic | P | |
|---|---|---|---|
Patients | 214 | 145 | - |
Chronological age at B2 (as referred by parents) (yr) | 7.9 ± 0.9 | 7.7 ± 1 | 0.013 |
Chronological age at diagnosis (yr) | 8.6 ± 1.2 | 8.1 ± 8.1 | < 0.001 |
Height SDS | 0.75 ± 1.02 | 0.63 ± 1.15 | 0.31 |
Weight SDS | 0.76 ± 0.93 | 0.74 ± 1.02 | 0.89 |
BMI SDS | 0.57 ± 0.86 | 0.51 ± 0.92 | 0.57 |
BMI-Status-n (%) | |||
Obese | 17 (8) | 14(9.7) | 0.430 |
Overweight | 48(22.6) | 24 (16.6) | 0.180 |
Normal | 144(67.9) | 103(71) | 0.306 |
Underweight | 3(1.4) | 4(2.8) | 0.300 |
Tanner stage at diagnosis-n(%) | |||
T II | 126(59.2) | 88(60.7) | 0.217 |
T III | 61(28.59) | 45(31) | 0.667 |
T IV | 20(9.3) | 12(8.3) | 0.697 |
T V | 6(2.8) | 0.085 | |
Bone age (yr) | 9.4 ± 1.42 | 9.14 ± 1.48 | 0.18 |
Bone age-chronological age (yr) | 0.94 ± 1.02 | 1.1 ± 0.91 | 0.182 |
Basal LH (IU/L) | 0.74 ± 1.6 | 0.78 ± 1.3 | 0.489 |
Basal estradiol (pg/ml) | 19.5 ± 14 | 16.5 ± 13 | 0.08 |
Peak LH at LHRH stimulation test (IU/L) | 6.6 ± 3.9 | 6.5 ± 4.7 | 0.6 |
Uterine length (mm) | 34.5 ± 9.6 | 39 ± 33 | 0.51 |
Ovarian volume (cm3) | 3 ± 2.3 | 2.4 ± 1.4 | 0.056 |
Diagnosis at the time of presentation | |||
Central Precocious Puberty, n (%) | 19 (8) | 42 (29) | < 0.001 |
Early pubertal variant, n (%) | 195 (91) | 103 (71) | <0.001 |
GnRH analogue treatment at presentation- n(%) | 16(7.7) | 40 (27.5) | < 0.001 |
Screen time (h/day) (n:35) | 2.6 | 4.1 | < 0.001 |
Physical activity (h/day) (n:35) | 2.7 | 2 | 0.81 |